SeqOnce is accelerating life science discoveries and improving patient outcomes by focusing on Next Generation Sequencing. We believe optimizing kit chemistries unlocks hidden potentials in existing platforms.
Real-world solutions for real-world science.
Founded in 2014 by brothers Joseph Dunham and Chris Angermeyer, SeqOnce is privately held. The founders have complementary skill sets with CSO Joseph Dunham’s strong background in molecular biology and technology development, and CEO Chris Angermeyer’s expertise in finance and operations. Backed by Venture Capital, SeqOnce is growing rapidly as it continues to launch new products.
SeqOnce’s leading commercial product slashes NGS preparation time over 75% compared to other kits, while also vastly simplifying the protocol to only three steps.
Want to accelerate your Illumina Sequencer? How about your career?